Full Professor(heuristic)

Pancreatic and Hepatic Oncology Research · Oncology

Compare more Oncology professors.

h-index105
i10-index342
Publications990
Citations55,424

Grants

10 total · 0 active

NIH #R25CA068647

Methods in Clinical Cancer Research Workshop

Amount
$200K–$300K
Period
1996-07-22 → 2023-12-31
PIs
1

Awarded at AMERICAN ASSOCIATION FOR CANCER RESEARCH

NIH #R01CA129963

Tailoring New Drugs in Pancreatic Cancer

Amount
$300K–$400K
Period
2007-09-21 → 2012-07-31
PIs
1

Awarded at JOHNS HOPKINS UNIVERSITY

NIH #R01CA116554

Individualized Treatment of Pancreatic Cancer

Amount
$200K–$300K
Period
2006-06-06 → 2011-04-30
PIs
1

Awarded at JOHNS HOPKINS UNIVERSITY

Active grants are a starting point, not proof of an opening. Confirm recruiting and funding with the professor, current students, and your written offer. Learn how to verify PhD funding →

All Grants

10 total · 0 active

NIH #R25CA068647

Methods in Clinical Cancer Research Workshop

Amount
$200K–$300K
Period
1996-07-22 → 2023-12-31
PIs
1

Awarded at AMERICAN ASSOCIATION FOR CANCER RESEARCH

NIH #R01CA129963

Tailoring New Drugs in Pancreatic Cancer

Amount
$300K–$400K
Period
2007-09-21 → 2012-07-31
PIs
1

Awarded at JOHNS HOPKINS UNIVERSITY

NIH #R01CA116554

Individualized Treatment of Pancreatic Cancer

Amount
$200K–$300K
Period
2006-06-06 → 2011-04-30
PIs
1

Awarded at JOHNS HOPKINS UNIVERSITY

NIH #R01CA104900

Determinants of Response to ZD1839 (1 R01-CA104900-01)

Amount
$300K–$400K
Period
2004-07-01 → 2008-04-30
PIs
1

Awarded at JOHNS HOPKINS UNIVERSITY

NIH #R21CA109283

Pharmacogenomics of Erlotinib

Amount
$200K–$300K
Period
2005-07-01 → 2007-12-31
PIs
1

Awarded at JOHNS HOPKINS UNIVERSITY

NIH #R01FD002527

Phase II Study of Rapamycin in Pancreatic Cancer

Amount
$400K–$500K
Period
2004-09-30 → 2007-09-27
PIs
1

Awarded at JOHNS HOPKINS UNIVERSITY

NIH #R21CA112919

Pharmacodynamic-guided Dose-finding Study of Rapamycin

Amount
$200K–$300K
Period
2004-09-17 → 2006-08-31
PIs
1

Awarded at JOHNS HOPKINS UNIVERSITY

NIH #R21CA094516

Biological Evaluation of ZD1839 in Colon Cancer

Amount
$300K–$400K
Period
2002-09-09 → 2004-08-31
PIs
1

Awarded at JOHNS HOPKINS UNIVERSITY

NIH #R21CA099209

Biological Evaluation of CCI-779 in Brain Tumors

Amount
$200K–$300K
Period
2002-06-21 → 2004-05-31
PIs
1

Awarded at JOHNS HOPKINS UNIVERSITY

NIH #P30CA006973

RESEARCH PHARMACY

Amount
$300K–$400K
Period
— → —
PIs
1

Awarded at JOHNS HOPKINS UNIVERSITY

Recent Public Signals

  1. New preprint: Sonic hedgehog inhibitor suppresses carcinoma associated fibroblasts to prime Gemcitabine/Nab-Paclitaxel and anti-CTLA4 immunotherapy as sequential first-line combination therapy in a Phase 1b/2 study in PDAC: NUMANTIA trial2025-12-15
  2. New paper: TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma (Journal of Clinical Oncology)2025-11-04

Are you this professor?

No account needed — verify once with your ORCID iD to set recruiting status and correct your rank.

Data Freshness

  • Publications as of 2026-07-09
  • Grants as of 2026-09-03

Data may not be current

Find elsewhere

Institution / lab homepage Search on ResearchGate

ORCID: 0000-0002-3765-3318

Professor Insights

Career Trajectory